Skip to main content

Table 1 Demographics and baseline characteristics

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

 

All patients

Patients with history of CVD

Elderly patients with hypertension and a history of CVD

DAPA

(N = 5936)

CTRL

(N = 3403)

DAPA

(n = 1856)

CTRL

(n = 1358)

DAPA

(n = 707a)

CTRL

(n = 556)

Age, mean (SD), years

56.9 (10.4)

58.1 (10.3)

62.4

62.9

70.2 (4.1)

70.1 (4.2)

  ≥65 years (%)

24.0

28.8

40.9

43.1

100

100

Race

  White, n (%)

4505 (75.9)

2644 (77.7)

1634 (88.0)

1199 (88.3)

634 (89.7)

521 (93.7)

  Otherb, n (%)

1431 (24.1)

759 (22.3)

222 (12.0)

159 (11.7)

73 (10.3)

35 (6.3)

BMI, mean (SD), kg/m2

31.3 (5.7)

31.6 (5.8)

32.4 (5.4)

32.5 (5.9)

31.8 (5.0)

32.1 (5.4)

T2DM duration, mean (SD), years

7.0 (7.5)

7.6 (7.7)c

11.1 (8.4)

11.2 (8.3)

13.4 (9.3)

13.0 (9.1)

History of CVD (%)

31.3

39.9

100

100

100

100

History of hypertension (%)

65.7

71.9

89.8

92.8

100

100

History of CHF (%)

3.9

4.8

12.6

12.0

15.4

15.3

Smoking history (%)

43.3

46.3

53.3

56.4

51.8

53.1

eGFR, mean (SD), mL/min/1.73 m2

83.9 (21.3)

83.6 (21.1)d

75.7 (19.5)

77.0 (19.5)e

69.9 (18.5)

71.7 (17.9)

LDL, mean (SD), mmol/L

2.78 (0.98)f

2.66 (0.96)g

2.47 (0.98)h

2.36 (0.92)i

2.32 (0.90)j

2.28 (0.89)k

SBP, mean (SD), mmHg

130.4 (15.7)l

131.1 (14.9)m

134.5 (15.4)n

133.7 (14.5)o

136.7 (15.7)p

135.6 (14.0)q

DBP, mean (SD), mmHg

78.8 (9.1)l

78.8 (8.9)m

78.0 (9.3)n

77.7 (9.1)o

76.1 (9.3)p

76.1 (9.0)q

Concomitant medications of interest:

   Any antihypertensive

3217 (54.2)

2061 (60.6)

1440 (86.4)

1085 (86.1)

604 (85.4)

476 (85.6)

   Diuretics

1509 (25.4)

960 (28.2)

788 (47.3)

604 (47.9)

363 (51.3)

282 (50.7)

   β-blockers

1604 (27.0)

1127 (33.1)

1045 (62.7)

819 (65.0)

454 (64.2)

367 (66.0)

   ACEi/ARBs

2938 (49.5)

1908 (56.1)

1327 (79.7)

1022 (81.1)

556 (78.6)

451 (81.1)

   Calcium channel blockers

1126 (19.0)

717 (21.1)

545 (32.7)

431 (34.2)

251 (35.5)

203 (36.5)

 Statins

2276 (38.3)

1582 (46.5)

1145 (68.7)

928 (73.7)

497 (70.3)

408 (73.4)

 Aspirin

1906 (32.1)

1322 (38.8)

1068 (64.1)

858 (68.1)

456 (64.5)

378 (68.0)

  1. ACEi angiotensin converting enzyme inhibitors, ARBS angiotensin receptor blockers, BMI body mass index, CHF congestive heart failure, CTRL control, CVD cardiovascular disease, DAPA dapagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, LDL low density lipoprotein cholesterol, SD standard deviation, SBP systolic blood pressure
  2. aTwo patients were not randomised to dapagliflozin, but were subsequently treated with dapagliflozin; b Other includes Black or African American, Asian and Other; c n = 3400; d n = 3402; e n = 1357; f n = 5742; g n = 3234; h n = 1821; i n = 1316; j n = 698; k n = 543; l n = 5619; m n = 3274; n n = 1824; o n = 1345; p n = 704; q n = 553
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840